PCSK9 inhibitors added to a statin after ischaemic stroke: promising, low-certainty signal

Design

Systematic review and meta-analysis of randomised trials, GRADE-assessed

Population

Adults with acute ischaemic stroke on a statin, with or without a PCSK9 inhibitor

Primary outcome

Functional independence (mRS 0–2) and recurrent ischaemic stroke

Effect

mRS 0–2 OR 2.17 (1.29–3.64); recurrent stroke OR 0.33 (0.16–0.69); certainty moderate to low

This meta-analysis pooled randomised trials comparing a PCSK9 inhibitor plus a statin with a statin alone in acute ischaemic stroke. Searches ran to May 2026.

Adding a PCSK9 inhibitor was associated with more patients functionally independent (modified Rankin 0–2: OR 2.17, 95% CI 1.29–3.64) and fewer recurrent strokes (OR 0.33, 0.16–0.69). LDL cholesterol fell by a further 0.66 mmol/L. Liver abnormalities, major cardiovascular events and total adverse events did not differ. The authors rated certainty as moderate for function and low for recurrence and safety.

The recurrence effect is far larger than lipid lowering produces in long-term outcome trials, which is a reason for caution rather than excitement: small trials, short follow-up and few events tend to inflate effects. The case for early, intensive LDL lowering after stroke is already strong. Whether a PCSK9 inhibitor in the acute phase adds to it needs larger trials before it changes practice.

• Start high-intensity statin therapy early after ischaemic stroke; that remains the evidence-based foundation.
• Consider a PCSK9 inhibitor where LDL stays above target on maximal tolerated statin and ezetimibe, as guidelines already allow.
• Do not add a PCSK9 inhibitor in the acute phase on this meta-analysis alone; the certainty is low.
• Short-term liver and adverse event rates were similar to statin alone in these trials.
• Cost limits PCSK9 inhibitor use in India; inclisiran and biosimilar options vary by centre.

Why it matters

It asks whether lipid lowering after stroke should start harder and earlier than current practice.

Don't overread it

A two-thirds cut in recurrent stroke from small, short trials is likely an overestimate and has not changed any guideline.

The statistics, in plain English

An odds ratio of 0.33 for recurrent stroke has a 95% interval of 0.16 to 0.69: the data fit anything from a modest to a very large benefit. GRADE 'low certainty' means the true effect could be substantially different. The LDL result had high heterogeneity (I² 86%), meaning the trials disagreed on how much extra lowering they achieved.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.